A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

被引：1
|
作者：
Lee, Hans C. [1 ]
Shah, Jatin J. [2 ]
Feng, Lei [3 ]
Morphey, Ashley [1 ]
Johnson, Ralph J. [1 ]
Wesson, Emily T. [1 ]
Wang, Michael L. [1 ]
Alexanian, Raymond [1 ]
Thomas, Sheeba K. [1 ]
Orlowski, Robert Z. [1 ,4 ]
Weber, Donna M. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, 1515 Holcombe Blvd,Unit 429, Houston, TX 77030 USA
[2] Karyopharm Therapeut, Newton, MA USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2019年 / 94卷 / 12期
关键词：
DARATUMUMAB; POMALIDOMIDE;
D O I：
10.1002/ajh.25633
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E319 / E322
页数：4
相关论文
共 50 条
  • [41] Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma
    Schmielau, J
    Teschendorf, C
    König, M
    Schmiegel, W
    Graeven, U
    LEUKEMIA & LYMPHOMA, 2005, 46 (04) : 567 - 569
  • [42] Thalidomide and dexamethasone combination for refractory multiple myeloma
    Dimopoulos, MA
    Zervas, K
    Kouvatseas, G
    Galani, E
    Grigoraki, V
    Kiamouris, C
    Vervessou, E
    Samantas, E
    Papadimitriou, C
    Economou, O
    Gika, D
    Panayiotidis, P
    Christakis, I
    Anagnostopoulos, N
    ANNALS OF ONCOLOGY, 2001, 12 (07) : 991 - 995
  • [43] Mature results of MM-011: A phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma
    Lazaryan, Aleksandr
    Hussein, Mohamad A.
    Reu, Frederic J.
    Faiman, Beth
    Habecker, Becky
    Karam, Mary Ann
    Reed, Janice
    Hamilton, Kimberly
    Waksman, Joel
    Bruening, Kellie
    Srkalovic, Gordan
    Andresen, Steven
    Kalaycio, Matthew
    Sweetenham, John W.
    Sobecks, Ronald
    Dean, Robert
    Knight, Robert
    Zeldis, Jerome B.
    Baz, Rachid
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (04) : 349 - 354
  • [44] A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Phase I results.
    Lunning, Matthew Alexander
    Ruan, Jia
    Nair, Sumithra
    Boruchov, Adam M.
    Byrne, Regina
    Gerecitano, John F.
    Hamlin, Paul A.
    Inserra, Beth
    Leonard, John
    Lynch, Peggy
    Matasar, Matthew J.
    Moskowitz, Alison J.
    Moskowitz, Craig
    Myskowski, Patricia L.
    Nolan, Patrick
    Palomba, Maria Lia
    Quefeld, Christiane
    Straus, David J.
    Zelenetz, Andrew David
    Horwitz, Steven M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [45] Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
    Dimopoulos, Meletios
    Spencer, Andrew
    Attal, Michael
    Prince, H. Miles
    Harousseau, Jean-Luc
    Dmoszynska, Anna
    San Miguel, Jesus
    Hellmann, Andrzej
    Facon, Thierry
    Foa, Robin
    Corso, Alessandro
    Masliak, Zvenyslava
    Olesnyckyj, Marta
    Yu, Zhinuan
    Patin, John
    Zeldis, Jerome B.
    Knight, Robert D.
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21): : 2123 - 2132
  • [46] Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
    Vesole, David H.
    Bilotti, Elizabeth
    Richter, Joshua R.
    McNeill, Ann
    McBride, Laura
    Raucci, Laura
    Anand, Palka
    Bednarz, Urszula
    Ivanovski, Kristin
    Smith, Judith
    Batra, Veena
    Aleman, Adolfo
    Sims, Taliah
    Guerrero, Laura
    Mato, Anthony
    Siegel, David S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 171 (01) : 52 - 59
  • [47] Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
    Dabkara, Deepak
    Bajpai, Jyoti
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2008, 29 (03) : 10 - 13
  • [48] A Phase Ib/II Trial of Selinexor Combined with Lenalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma
    White, Darrell J.
    Bahlis, Nizar J.
    Venner, Christopher P.
    Schiller, Gary J.
    Gasparetto, Cristina J.
    Sutherland, Heather J.
    Sebag, Michael
    Lentzsch, Suzanne
    Kotb, Rami
    Bensinger, William
    Lipe, Brea C.
    Chen, Christine I.
    Del Col, Aldo
    Kauffman, Michael G.
    Shacham, Sharon
    Jeha, Jacqueline
    Saint-Martin, Jean-Richard
    Shah, Jatin
    LeBlanc, Richard
    BLOOD, 2017, 130
  • [49] Comparison of lenalidomide in combination with dexamethasone to dexamethasone alone in patients who have received prior thalidomide in relapsed or refractory multiple myeloma.
    Wang, M.
    Knight, R.
    Dimopoulos, M.
    Siegel, D.
    Rajkumar, S. V.
    Facon, T.
    Yu, Z.
    Zeldis, J.
    Olesnyckyj, M.
    Weber, D. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 427S - 427S
  • [50] A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma
    Prince, HM
    Mileshkin, L
    Roberts, A
    Ganju, V
    Underhill, C
    Catalano, J
    Bell, R
    Seymour, JF
    Westerman, D
    Simmons, PJ
    Lillie, K
    Milner, AD
    Di Iulio, J
    Zeldis, JB
    Ramsay, R
    CLINICAL CANCER RESEARCH, 2005, 11 (15) : 5504 - 5514
12345